Box 603 • 10132 • Stockholm • Sweden

Recipharm

Swedish CDMO recognised for its commitment to its French operations

By Recipharm ·

Recipharm's four French facilities now serve over 50 of its customers worldwide, including a number of top 20 pharma firms.

Recipharm has received the “le Prix d’Excellence 2017 - Spécial Sciences de la vie” in recognition for its commitment to its French operations. The award was presented by the Swedish Chamber of Commerce in France.

Swedish CDMO recognised for its commitment to its French operations
The Prix D'Excellence Awards ceremony - Thomas Eldered, Recipharm CEO collecting their award.

The award acknowledges examples of best practice in the Franco-Swedish business community. As part of the application process, Recipharm was assessed on its commercial success, profitability, technological innovation, quality and continued commitment to its operations in France.

Over the course of its 10-year history in France, Recipharm has increased its presence significantly and its operations in the country now account for 21% of the company’s overall sales, with 73% of those sales being exported across the globe.

Recipharm, which established its French operations in 2007, now operates four manufacturing facilities in the country, located in Fontaine-les-Dijon, Pessac, Monts and Kaysersberg. From these facilities, the CDMO provides a broad range of development and manufacturing services across areas including solid dosage formulation, sterile injectables manufacturing and blow-fill-seal capabilities to a global customer base.

Jean-François Hilaire, Executive Vice President Strategy and Global Integration at Recipharm said: “We established our French operations 10 years ago to cater for demand in Europe and offer easy market access to our customers. Since then we have acquired four sites and made substantial investments into our facilities, including an EUR 18 million investment in 2016 into our blow-fill seal capability in Kaysersberg to meet customer demand in the US, Turkey, Australia and Canada."

“Our French facilities now serve over 50 of our customers worldwide, including a number of top 20 pharma firms, and employ over 20% of our staff. We have ongoing plans to grow our operations in the country and hope to see this positive trajectory continue for many years to come.”

Thomas Eldered, CEO at Recipharm added “I am honoured that Recipharm has been acknowledged for our decade-long commitment to France. We have been very pleased with the development of our business there and I would like to thank the Swedish Chamber of Commerce in France for recognising this.”

Read More


Go to company page 

Categories

Market News

Other news in “Market News”

M&A activity and investor cash expected to re-invigorate pharma and biotech in 2018

M&A activity and investor cash expected to re-invigorate pharma and biotech in 2018 

6 Dec 2017
SGS launches new large molecule bioanalytical services

SGS launches new large molecule bioanalytical services 

8 Dec 2017
Global ADC Bio clients to benefit from new dedicated bioconjugation facility

Global ADC Bio clients to benefit from new dedicated bioconjugation facility 

7 Dec 2017